nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0333	0.332	CbGbCtD
Everolimus—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.031	0.308	CbGbCtD
Everolimus—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0142	0.142	CbGbCtD
Everolimus—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.013	0.13	CbGbCtD
Everolimus—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00889	0.0885	CbGbCtD
Everolimus—Temsirolimus—ABCB1—peripheral nervous system neoplasm	0.00226	0.362	CrCbGaD
Everolimus—Sirolimus—ABCB1—peripheral nervous system neoplasm	0.00199	0.319	CrCbGaD
Everolimus—Tacrolimus—ABCB1—peripheral nervous system neoplasm	0.00199	0.319	CrCbGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000512	0.00287	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PTPN11—peripheral nervous system neoplasm	0.000512	0.00287	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000507	0.00285	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000503	0.00282	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—PTPN11—peripheral nervous system neoplasm	0.000489	0.00275	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000485	0.00272	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	0.000482	0.00271	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000482	0.0027	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000479	0.00269	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—PTPN11—peripheral nervous system neoplasm	0.000462	0.0026	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—NRAS—peripheral nervous system neoplasm	0.000461	0.00259	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—PTPN11—peripheral nervous system neoplasm	0.00046	0.00258	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—PTPN11—peripheral nervous system neoplasm	0.000458	0.00257	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000458	0.00257	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NTRK1—peripheral nervous system neoplasm	0.000456	0.00256	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—PTPN11—peripheral nervous system neoplasm	0.000456	0.00256	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—PTPN11—peripheral nervous system neoplasm	0.000453	0.00254	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—NRAS—peripheral nervous system neoplasm	0.000449	0.00252	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTPN11—peripheral nervous system neoplasm	0.000447	0.00251	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—peripheral nervous system neoplasm	0.000444	0.00249	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—peripheral nervous system neoplasm	0.000441	0.00248	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000437	0.00245	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—NRAS—peripheral nervous system neoplasm	0.000433	0.00243	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—NRAS—peripheral nervous system neoplasm	0.000433	0.00243	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PTPN11—peripheral nervous system neoplasm	0.000427	0.00239	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTPN11—peripheral nervous system neoplasm	0.000427	0.00239	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PTPN11—peripheral nervous system neoplasm	0.000427	0.00239	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	0.000424	0.00238	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD34—peripheral nervous system neoplasm	0.000423	0.00238	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PTPN11—peripheral nervous system neoplasm	0.000423	0.00237	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—AKT1—peripheral nervous system neoplasm	0.000422	0.00237	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000422	0.00237	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PTPN11—peripheral nervous system neoplasm	0.000419	0.00235	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000418	0.00235	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PTPN11—peripheral nervous system neoplasm	0.000417	0.00234	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—peripheral nervous system neoplasm	0.000417	0.00234	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—HRAS—peripheral nervous system neoplasm	0.000413	0.00232	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—HRAS—peripheral nervous system neoplasm	0.000413	0.00232	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000406	0.00228	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PPP3R1—peripheral nervous system neoplasm	0.000406	0.00228	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB2—peripheral nervous system neoplasm	0.000404	0.00227	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.0004	0.00224	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PTPN11—peripheral nervous system neoplasm	0.000395	0.00222	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—HRAS—peripheral nervous system neoplasm	0.000394	0.00221	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00039	0.00219	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—NRAS—peripheral nervous system neoplasm	0.000389	0.00219	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—peripheral nervous system neoplasm	0.000387	0.00217	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—peripheral nervous system neoplasm	0.000384	0.00215	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000383	0.00215	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000381	0.00214	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000378	0.00212	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	0.000373	0.00209	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000369	0.00207	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—AKT1—peripheral nervous system neoplasm	0.000365	0.00205	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—AKT1—peripheral nervous system neoplasm	0.000365	0.00205	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—ERBB2—peripheral nervous system neoplasm	0.000364	0.00204	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NRAS—peripheral nervous system neoplasm	0.000362	0.00203	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB2—peripheral nervous system neoplasm	0.000362	0.00203	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—peripheral nervous system neoplasm	0.000362	0.00203	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.000361	0.00203	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB2—peripheral nervous system neoplasm	0.00036	0.00202	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—NRAS—peripheral nervous system neoplasm	0.00036	0.00202	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB2—peripheral nervous system neoplasm	0.000358	0.00201	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	0.000356	0.002	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—AKT1—peripheral nervous system neoplasm	0.000356	0.002	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—peripheral nervous system neoplasm	0.000354	0.00199	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—peripheral nervous system neoplasm	0.000353	0.00198	CbGpPWpGaD
Everolimus—MTOR—SREBP signalling—AKT1—peripheral nervous system neoplasm	0.000352	0.00198	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—AKT1—peripheral nervous system neoplasm	0.000352	0.00198	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ENO2—peripheral nervous system neoplasm	0.000352	0.00197	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000347	0.00195	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD55—peripheral nervous system neoplasm	0.000339	0.0019	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—HRAS—peripheral nervous system neoplasm	0.000337	0.00189	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB2—peripheral nervous system neoplasm	0.000337	0.00189	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—peripheral nervous system neoplasm	0.000337	0.00189	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB2—peripheral nervous system neoplasm	0.000337	0.00189	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB2—peripheral nervous system neoplasm	0.000334	0.00188	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—peripheral nervous system neoplasm	0.000331	0.00186	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB2—peripheral nervous system neoplasm	0.00033	0.00185	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000329	0.00185	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000328	0.00184	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—peripheral nervous system neoplasm	0.000328	0.00184	CbGpPWpGaD
Everolimus—MTOR—Disease—GNS—peripheral nervous system neoplasm	0.000326	0.00183	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—peripheral nervous system neoplasm	0.000325	0.00183	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—peripheral nervous system neoplasm	0.000317	0.00178	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—peripheral nervous system neoplasm	0.000317	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—peripheral nervous system neoplasm	0.000313	0.00176	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB2—peripheral nervous system neoplasm	0.000312	0.00175	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000308	0.00173	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—peripheral nervous system neoplasm	0.000308	0.00173	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	0.000301	0.00169	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000301	0.00169	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000299	0.00168	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	0.000298	0.00167	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—peripheral nervous system neoplasm	0.000295	0.00166	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—peripheral nervous system neoplasm	0.000294	0.00165	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000294	0.00165	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000291	0.00163	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.00029	0.00163	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	0.000285	0.0016	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—peripheral nervous system neoplasm	0.000285	0.0016	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000284	0.0016	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC2A1—peripheral nervous system neoplasm	0.000283	0.00159	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	0.000281	0.00158	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000277	0.00156	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—NRAS—peripheral nervous system neoplasm	0.000277	0.00155	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	0.000275	0.00155	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	0.000274	0.00154	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—peripheral nervous system neoplasm	0.000273	0.00153	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000271	0.00152	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	0.000269	0.00151	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—AKT1—peripheral nervous system neoplasm	0.000266	0.00149	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	0.000265	0.00149	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—peripheral nervous system neoplasm	0.000263	0.00148	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—AKT1—peripheral nervous system neoplasm	0.000259	0.00146	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—AKT1—peripheral nervous system neoplasm	0.000257	0.00145	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD34—peripheral nervous system neoplasm	0.000257	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	0.000256	0.00144	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	0.000256	0.00144	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—peripheral nervous system neoplasm	0.000256	0.00144	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	0.000256	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	0.000254	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	0.000252	0.00141	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	0.000252	0.00141	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	0.000252	0.00141	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	0.000251	0.00141	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	0.000248	0.00139	CbGpPWpGaD
Everolimus—MTOR—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000247	0.00139	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—peripheral nervous system neoplasm	0.000237	0.00133	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.000234	0.00131	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.00023	0.00129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000229	0.00128	CbGpPWpGaD
Everolimus—MTOR—Disease—PPP3R1—peripheral nervous system neoplasm	0.000228	0.00128	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000227	0.00127	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	0.000225	0.00126	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000223	0.00125	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	0.000221	0.00124	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000219	0.00123	CbGpPWpGaD
Everolimus—MTOR—Immune System—NCAM1—peripheral nervous system neoplasm	0.000218	0.00123	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	0.000215	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000213	0.0012	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.000212	0.00119	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000208	0.00117	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—peripheral nervous system neoplasm	0.000203	0.00114	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	0.000202	0.00114	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	0.000201	0.00113	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000201	0.00113	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	0.0002	0.00112	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—HRAS—peripheral nervous system neoplasm	0.000199	0.00112	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	0.000199	0.00112	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO2—peripheral nervous system neoplasm	0.000198	0.00111	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	0.000197	0.0011	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	0.000195	0.0011	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	0.00019	0.00107	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000188	0.00106	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	0.000188	0.00105	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	0.000188	0.00105	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—peripheral nervous system neoplasm	0.000188	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.000187	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	0.000186	0.00104	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	0.000184	0.00103	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	0.000183	0.00103	CbGpPWpGaD
Everolimus—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000256	CcSEcCtD
Everolimus—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000255	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000183	0.00102	CbGpPWpGaD
Everolimus—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000254	CcSEcCtD
Everolimus—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000254	CcSEcCtD
Everolimus—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000254	CcSEcCtD
Everolimus—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000181	0.000254	CcSEcCtD
Everolimus—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000181	0.000253	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—AKT1—peripheral nervous system neoplasm	0.00018	0.00101	CbGpPWpGaD
Everolimus—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000179	0.000251	CcSEcCtD
Everolimus—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000179	0.00025	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	0.000179	0.001	CbGpPWpGaD
Everolimus—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000249	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	0.000178	0.000998	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000178	0.000998	CbGpPWpGaD
Everolimus—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000249	CcSEcCtD
Everolimus—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000178	0.000249	CcSEcCtD
Everolimus—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000248	CcSEcCtD
Everolimus—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000177	0.000248	CcSEcCtD
Everolimus—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000248	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	0.000177	0.000993	CbGpPWpGaD
Everolimus—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000177	0.000247	CcSEcCtD
Everolimus—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000246	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	0.000176	0.000988	CbGpPWpGaD
Everolimus—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000245	CcSEcCtD
Everolimus—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000245	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000175	0.000245	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000245	CcSEcCtD
Everolimus—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000175	0.000244	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.000175	0.000981	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000174	0.000977	CbGpPWpGaD
Everolimus—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000174	0.000243	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—peripheral nervous system neoplasm	0.000174	0.000975	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	0.000174	0.000974	CbGpPWpGaD
Everolimus—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000173	0.000242	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000173	0.000972	CbGpPWpGaD
Everolimus—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000241	CcSEcCtD
Everolimus—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000241	CcSEcCtD
Everolimus—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000172	0.000241	CcSEcCtD
Everolimus—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000172	0.000241	CcSEcCtD
Everolimus—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000172	0.00024	CcSEcCtD
Everolimus—MTOR—Immune System—IFNB1—peripheral nervous system neoplasm	0.000171	0.000962	CbGpPWpGaD
Everolimus—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000239	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000239	CcSEcCtD
Everolimus—Constipation—Etoposide—peripheral nervous system neoplasm	0.00017	0.000238	CcSEcCtD
Everolimus—Pain—Etoposide—peripheral nervous system neoplasm	0.00017	0.000238	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000238	CcSEcCtD
Everolimus—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000238	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000238	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000238	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000236	CcSEcCtD
Everolimus—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000169	0.000236	CcSEcCtD
Everolimus—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000168	0.000235	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000235	CcSEcCtD
Everolimus—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000234	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000166	0.000933	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000232	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000166	0.00093	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	0.000166	0.00093	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	0.000166	0.00093	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	0.000166	0.00093	CbGpPWpGaD
Everolimus—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000231	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.00023	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000164	0.00023	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000164	0.00023	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	0.000164	0.000922	CbGpPWpGaD
Everolimus—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000229	CcSEcCtD
Everolimus—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000164	0.000229	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000228	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000163	0.000228	CcSEcCtD
Everolimus—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000163	0.000228	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	0.000163	0.000913	CbGpPWpGaD
Everolimus—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000162	0.000227	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000227	CcSEcCtD
Everolimus—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000227	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	0.000162	0.000909	CbGpPWpGaD
Everolimus—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000161	0.000225	CcSEcCtD
Everolimus—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000161	0.000225	CcSEcCtD
Everolimus—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00016	0.000224	CcSEcCtD
Everolimus—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00016	0.000224	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00016	0.000897	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.00016	0.000896	CbGpPWpGaD
Everolimus—MTOR—Disease—SLC2A1—peripheral nervous system neoplasm	0.000159	0.000895	CbGpPWpGaD
Everolimus—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000223	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	0.000159	0.000893	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTPN11—peripheral nervous system neoplasm	0.000158	0.000889	CbGpPWpGaD
Everolimus—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000221	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000221	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000221	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000221	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000158	0.00022	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000158	0.00022	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.00022	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.00022	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000157	0.00022	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000157	0.00022	CcSEcCtD
Everolimus—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000219	CcSEcCtD
Everolimus—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000156	0.000219	CcSEcCtD
Everolimus—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000156	0.000218	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000218	CcSEcCtD
Everolimus—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000217	CcSEcCtD
Everolimus—Rash—Vincristine—peripheral nervous system neoplasm	0.000155	0.000217	CcSEcCtD
Everolimus—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000155	0.000217	CcSEcCtD
Everolimus—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000217	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000216	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000216	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000216	CcSEcCtD
Everolimus—Headache—Vincristine—peripheral nervous system neoplasm	0.000154	0.000216	CcSEcCtD
Everolimus—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000214	CcSEcCtD
Everolimus—MTOR—B Cell Activation—AKT1—peripheral nervous system neoplasm	0.000153	0.000861	CbGpPWpGaD
Everolimus—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000214	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000213	CcSEcCtD
Everolimus—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000152	0.000212	CcSEcCtD
Everolimus—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000149	0.000208	CcSEcCtD
Everolimus—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000148	0.000833	CbGpPWpGaD
Everolimus—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000206	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000147	0.000205	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000147	0.000824	CbGpPWpGaD
Everolimus—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000205	CcSEcCtD
Everolimus—Nausea—Vincristine—peripheral nervous system neoplasm	0.000146	0.000204	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000204	CcSEcCtD
Everolimus—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000204	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000204	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000204	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000204	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000202	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000202	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000201	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.0002	CcSEcCtD
Everolimus—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000143	0.0002	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.0002	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000143	0.0002	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000199	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—peripheral nervous system neoplasm	0.000142	0.0008	CbGpPWpGaD
Everolimus—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000199	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000198	CcSEcCtD
Everolimus—Chills—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000197	CcSEcCtD
Everolimus—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000141	0.000197	CcSEcCtD
Everolimus—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000194	CcSEcCtD
Everolimus—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000138	0.000193	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000193	CcSEcCtD
Everolimus—Rash—Cisplatin—peripheral nervous system neoplasm	0.000137	0.000192	CcSEcCtD
Everolimus—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000137	0.000192	CcSEcCtD
Everolimus—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000191	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000191	CcSEcCtD
Everolimus—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000136	0.000191	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.00019	CcSEcCtD
Everolimus—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000189	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000189	CcSEcCtD
Everolimus—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000189	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000188	CcSEcCtD
Everolimus—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000185	CcSEcCtD
Everolimus—MTOR—Immune System—HGF—peripheral nervous system neoplasm	0.000132	0.000743	CbGpPWpGaD
Everolimus—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000185	CcSEcCtD
Everolimus—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000132	0.000184	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000184	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000184	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000183	CcSEcCtD
Everolimus—MTOR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	0.000131	0.000735	CbGpPWpGaD
Everolimus—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000183	CcSEcCtD
Everolimus—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000129	0.000181	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000129	0.00018	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.00018	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	0.000128	0.000717	CbGpPWpGaD
Everolimus—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000178	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000178	CcSEcCtD
Everolimus—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000127	0.000177	CcSEcCtD
Everolimus—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000177	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000177	CcSEcCtD
Everolimus—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000177	CcSEcCtD
Everolimus—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000176	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	0.000126	0.000706	CbGpPWpGaD
Everolimus—Rash—Etoposide—peripheral nervous system neoplasm	0.000126	0.000176	CcSEcCtD
Everolimus—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000126	0.000176	CcSEcCtD
Everolimus—FKBP1A—Disease—ERBB2—peripheral nervous system neoplasm	0.000125	0.000703	CbGpPWpGaD
Everolimus—Headache—Etoposide—peripheral nervous system neoplasm	0.000125	0.000175	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000175	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000173	CcSEcCtD
Everolimus—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000173	CcSEcCtD
Everolimus—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000172	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000171	CcSEcCtD
Everolimus—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000171	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.00017	CcSEcCtD
Everolimus—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000169	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000168	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.00012	0.000674	CbGpPWpGaD
Everolimus—Cough—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000167	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000167	CcSEcCtD
Everolimus—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000166	CcSEcCtD
Everolimus—Nausea—Etoposide—peripheral nervous system neoplasm	0.000118	0.000166	CcSEcCtD
Everolimus—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000165	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000164	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000164	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000163	CcSEcCtD
Everolimus—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000163	CcSEcCtD
Everolimus—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000163	CcSEcCtD
Everolimus—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000163	CcSEcCtD
Everolimus—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000162	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000162	CcSEcCtD
Everolimus—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000161	CcSEcCtD
Everolimus—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.00016	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000159	CcSEcCtD
Everolimus—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000159	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000159	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	0.000113	0.000633	CbGpPWpGaD
Everolimus—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000157	CcSEcCtD
Everolimus—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000156	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000156	CcSEcCtD
Everolimus—Infection—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000155	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000111	0.000623	CbGpPWpGaD
Everolimus—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000155	CcSEcCtD
Everolimus—Shock—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000154	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000153	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000153	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000153	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000153	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000153	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000152	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000151	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000151	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000151	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000151	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.00015	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.00015	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000149	CcSEcCtD
Everolimus—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000149	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000148	CcSEcCtD
Everolimus—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000146	CcSEcCtD
Everolimus—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000145	CcSEcCtD
Everolimus—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000144	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000103	0.000576	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000142	CcSEcCtD
Everolimus—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000142	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000142	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000142	CcSEcCtD
Everolimus—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000141	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000141	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.00014	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.0001	0.00014	CcSEcCtD
Everolimus—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.0001	0.000563	CbGpPWpGaD
Everolimus—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.00014	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NRAS—peripheral nervous system neoplasm	9.96e-05	0.000559	CbGpPWpGaD
Everolimus—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	9.96e-05	0.000139	CcSEcCtD
Everolimus—Somnolence—Epirubicin—peripheral nervous system neoplasm	9.94e-05	0.000139	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—peripheral nervous system neoplasm	9.86e-05	0.000138	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	9.84e-05	0.000138	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.79e-05	0.000549	CbGpPWpGaD
Everolimus—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	9.71e-05	0.000136	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	0.000135	CcSEcCtD
Everolimus—MTOR—Immune System—PTPN11—peripheral nervous system neoplasm	9.65e-05	0.000542	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	9.65e-05	0.000135	CcSEcCtD
Everolimus—Fatigue—Epirubicin—peripheral nervous system neoplasm	9.64e-05	0.000135	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	9.57e-05	0.000537	CbGpPWpGaD
Everolimus—Constipation—Epirubicin—peripheral nervous system neoplasm	9.56e-05	0.000134	CcSEcCtD
Everolimus—Pain—Epirubicin—peripheral nervous system neoplasm	9.56e-05	0.000134	CcSEcCtD
Everolimus—FKBP1A—Disease—NRAS—peripheral nervous system neoplasm	9.53e-05	0.000535	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	9.42e-05	0.000132	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—peripheral nervous system neoplasm	9.35e-05	0.000131	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	9.29e-05	0.00013	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	9.22e-05	0.000129	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000129	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—peripheral nervous system neoplasm	9.19e-05	0.000129	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	9.14e-05	0.000128	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	9.1e-05	0.000127	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000126	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.98e-05	0.000504	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000125	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—peripheral nervous system neoplasm	8.92e-05	0.000125	CcSEcCtD
Everolimus—MTOR—Disease—PTPN11—peripheral nervous system neoplasm	8.91e-05	0.0005	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—peripheral nervous system neoplasm	8.87e-05	0.000498	CbGpPWpGaD
Everolimus—Constipation—Doxorubicin—peripheral nervous system neoplasm	8.84e-05	0.000124	CcSEcCtD
Everolimus—Pain—Doxorubicin—peripheral nervous system neoplasm	8.84e-05	0.000124	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000124	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000124	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.77e-05	0.000492	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	8.52e-05	0.000119	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	8.46e-05	0.000118	CcSEcCtD
Everolimus—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	8.23e-05	0.000115	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000114	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000114	CcSEcCtD
Everolimus—Asthenia—Epirubicin—peripheral nervous system neoplasm	8.02e-05	0.000112	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.96e-05	0.000447	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—peripheral nervous system neoplasm	7.91e-05	0.000111	CcSEcCtD
Everolimus—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	7.65e-05	0.000107	CcSEcCtD
Everolimus—MTOR—Immune System—ERBB2—peripheral nervous system neoplasm	7.63e-05	0.000428	CbGpPWpGaD
Everolimus—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	7.62e-05	0.000107	CcSEcCtD
Everolimus—Asthenia—Doxorubicin—peripheral nervous system neoplasm	7.42e-05	0.000104	CcSEcCtD
Everolimus—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.39e-05	0.000103	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—peripheral nervous system neoplasm	7.32e-05	0.000102	CcSEcCtD
Everolimus—MTOR—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.29e-05	0.000409	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	7.25e-05	0.000407	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—peripheral nervous system neoplasm	7.11e-05	9.94e-05	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	7.08e-05	9.89e-05	CcSEcCtD
Everolimus—Rash—Epirubicin—peripheral nervous system neoplasm	7.05e-05	9.85e-05	CcSEcCtD
Everolimus—MTOR—Disease—ERBB2—peripheral nervous system neoplasm	7.04e-05	0.000395	CbGpPWpGaD
Everolimus—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.04e-05	9.84e-05	CcSEcCtD
Everolimus—Headache—Epirubicin—peripheral nervous system neoplasm	7e-05	9.79e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7e-05	0.000393	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—peripheral nervous system neoplasm	6.97e-05	0.000391	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	6.95e-05	0.00039	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.84e-05	9.56e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	6.69e-05	0.000376	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.67e-05	0.000374	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—peripheral nervous system neoplasm	6.64e-05	9.28e-05	CcSEcCtD
Everolimus—Vomiting—Doxorubicin—peripheral nervous system neoplasm	6.57e-05	9.19e-05	CcSEcCtD
Everolimus—Rash—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	9.12e-05	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	6.51e-05	9.11e-05	CcSEcCtD
Everolimus—Headache—Doxorubicin—peripheral nervous system neoplasm	6.48e-05	9.06e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.44e-05	0.000361	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.24e-05	0.00035	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.21e-05	0.000349	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.18e-05	0.000347	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—peripheral nervous system neoplasm	6.15e-05	0.000345	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.14e-05	8.59e-05	CcSEcCtD
Everolimus—MTOR—Immune System—NRAS—peripheral nervous system neoplasm	5.8e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—peripheral nervous system neoplasm	5.36e-05	0.000301	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.1e-05	0.000286	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—peripheral nervous system neoplasm	4.99e-05	0.00028	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.93e-05	0.000277	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.88e-05	0.000274	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.48e-05	0.000251	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.39e-05	0.000247	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.31e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—peripheral nervous system neoplasm	4.25e-05	0.000238	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—peripheral nervous system neoplasm	3.92e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.75e-05	0.000211	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—peripheral nervous system neoplasm	3.75e-05	0.00021	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	3.71e-05	0.000208	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.54e-05	0.000199	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.5e-05	0.000196	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.49e-05	0.000196	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—peripheral nervous system neoplasm	3.46e-05	0.000194	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.87e-05	0.000161	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.85e-05	0.00016	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.8e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.74e-05	0.000154	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.42e-05	0.000136	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	7.69e-06	4.32e-05	CbGpPWpGaD
